Αποτελέσματα Αναζήτησης
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a longitudinal, multi-center, observational study. The overall goal of ADNI is to validate biomarkers for Alzheimer’s disease (AD) clinical trials.
- About
About - ADNI | Alzheimer's Disease Neuroimaging Initiative
- News & Publications
News & Publications - ADNI | Alzheimer's Disease...
- HELP / FAQ
HELP / FAQ - ADNI | Alzheimer's Disease Neuroimaging...
- About
22 Ιουλ 2015 · ! 2 PROTOCOL SYNOPSIS Title Alzheimer’s Disease Neuroimaging Initiative 2 (ADNI2) Primary Objective The major goals of ADNI2 are to: 1. Determine the relationships among clinical, imaging, genetic, and biochemical biomarker characteristics of the entire spectrum of Alzheimer’s Disease (AD), as the pathology evolves from normal
30 Ιουν 2011 · Clinical data from the ADNI 1, ADNI GO and ADNI 2 phases of the project are now available in the the ADNI Repository (IDA). Once logged in, you may peruse and download assessment, medical history, biospecimen and other data from the DOWNLOAD | Study Data menu. See INSTRUCTIONS for more information.
The baseline diagnoses are encoded in two ways in the ADNI Merge Dataset. The first encoding is as follows: CN: Cognitively Normal; MCI: Mild Cognitive Impairment; Dementia: Alzheimer’s Disease or other Dementia. The second encoding is as follows: CN: Cognitively Normal; EMCI: Early Mild Cognitive Impairment; LMCI: Late Mild Cognitive Impairment
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a large, open-access database that contains hundreds of brain scans from both healthy controls and people with Alzheimer’s.
13 Αυγ 2024 · The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a public-private partnership aimed at studying cognitive aging, MCI, and early Alzheimer's to evaluate biomarkers.
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a longitudinal multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer’s disease (AD).